A High Throughput Drug Discovery for Intracellular Neurodegenerative Disease-Associated Targets using the LI-COR® Odyssey® Near Infrared Imaging System
11 January 2016
Intracellular abnormal tau accumulation has been indicated in Alzheimer's disease (AD) progression. The LI-COR® Odyssey® scanner has been used to develop a novel, 96-well cell-based assay suited for high throughput detection of changes in tau protein levels. The dual near-infrared detection capability of the LI-COR® Odyssey® scanner allows for simultaneous first-pass estimations of toxicity by measuring glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels within the same well. Using this system, we have identified a panel of novel HSP90 inhibitors with potent tau-reducing activity.